Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olopatadine 0.2% QD vs 0.1% BID in allergic conjunctivitis (China, Phase III)
CTR20140902Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olopatadine in allergic conjunctivitis (AC), sponsored by Alcon Inc.. Started Jan 2015; status: completed.
02
Drugs
olopatadine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on CTR20140902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140902.